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Abstract
Introduction: Leuprolide acetate is a synthetic analog of gonadotropin-releasing hormone used for the treatment
of prostate cancer. Its side effects are hot flashes, nausea, and fatigue. We report a case of a patient with proximal
inflammatory myopathy accompanied by severe rhabdomyolysis and renal failure following the second application
of leuprolide acetate. Drug withdrawal and steroid therapy resulted in remission within six weeks of the diagnosis.
To the best of our knowledge, our case report describes the second case of leuprolide acetate-induced
inflammatory myopathy and the first case of severe leuprolide acetate-induced rhabdomyolysis and renal failure in
the literature.
Case presentation: A 64-year-old Swiss Caucasian man was admitted to the hospital because of progressive
proximal muscle weakness, dyspnea, and oliguria. He had been treated twice with leuprolide acetate in monthly
doses. We performed a muscle biopsy, which excluded other causes of myopathy. The patient’s renal failure and
rhabdomyolysis were treated with rehydration and steroid therapy.
Conclusion: The aim of our case report is to highlight the rare but severe side effects associated with leuprolide
acetate therapy used to treat patients with inflammatory myopathy: severe rhabdomyolysis and renal failure.
Introduction
The etiology of myopathy includes congenital disorders,
immunologic processes, malignancies, infections, endo-
crinopathies, alcohol ingestion and adverse drug reac-
tions (particularly statins), immunosuppressive agents,
and nucleoside analog reverse transcriptase inhibitors
[1-5]. Drugs can exert myotoxic effects on muscles
through mechanisms that are direct (for example, alco-
hol ingestion, statins, or anti-malarial agents), immuno-
logical (for example, interferon a), or indirect (for
example, drug-induced hypokalemia, hyperthermia, or
seizures). Myositis can be associated with different can-
cers, mainly lung and breast cancers, but also prostate
cancer. In one study, cancer was diagnosed in 9% of 396
patients with polymyositis, and of the 168 men with
polymyositis, four had prostate cancer [6]. In another
study, of 309 patients with dermatomyositis or
polymyositis, 11.9% had cancer and one of these had
prostate cancer [7]. Myopathy might affect all muscles
or only proximal muscles, as well as pharyngeal muscles.
Case report
A 64-year-old Swiss Caucasian man patient with weak
urinary flow and an elevated serum prostate-specific
antigen (PSA) level of 130 μg/L was diagnosed with ade-
nocarcinoma of the prostate on the basis of a biopsy
(Gleason grade G3, Gleason score 4 + 4 = 8). A chest
X-ray obtained for further staging showed a solitary
node 9 mm in size in the left lower lung lobe. A com-
puted tomographic scan of the patient’s abdomen and
skeletal nuclear scintigraphy revealed no further suspi-
cious malignancies. Leuprolide acetate therapy delivered
as a monthly dose was initiated. After two months of
therapy, his serum PSA level decreased to 7 μg/L, and a
chest X-ray showed complete regression of the lung
node. A second dose of leuprolide acetate delivered
every three months was applied. Two months later the
patient was admitted to the hospital because of
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progressive proximal muscle weakness of six weeks’
duration; slight, intermittent proximal muscle pain; dys-
pnea; and oliguria. He was treated with irbesartan and
hydrochlorothiazide (CoAprovel® 150/12.5 mg Sanofi
Pharma Bristol - Myers Squibb SNC, 174 Avenue de
France F - 75013 Paris, France) because of arterial
hypertension and tamsulosin (Pradif T® Boehringer
Ingelheim GmbH, Dufourstrasse 54 CH 4002 Basel,
Switzerland) because of weak urinary flow. He did not
drink alcohol but smoked one pack of cigarettes per
day. At the time of admission, the patient was alert, his
body temperature was 38.6°C, his blood pressure was
140/80 mmHg, his heart rate was 80 beats/minute, his
breathing rate was 20 breaths/minute, and his oxygen
saturation level was 85% while breathing ambient air.
He had edema in his lower legs. Painless muscle weak-
ness prevented him from standing or sitting. He had
normal strength in both his hands and his feet, but
active lifting of his head, legs, and arms was barely pos-
sible while he was supine, and his speech was slurred.
His reflexes, eye movements, and cranial nerve function
were normal. He had no skin lesions. A chest X-ray
showed right lung infiltration consistent with aspiration
pneumonia. No signs of lung fibrosis were observed. His
electrocardiogram was normal. His laboratory values
were as follows: hemoglobin 148 g/L, leukocyte count
14.7 × 109/L, erythrocyte sedimentation rate 14 mm/
hour, creatine kinase 121,530 U/L, C-reactive protein 39
mg/L, creatinine 51 μmol/L, BUN 6.4 mmol/L, sodium
122 mmol/L, and potassium 4.3 mmol/L. His serum 25-
OH vitamin D level and thyroid gland function were
normal, and his human immunodeficiency virus test was
negative. MRI of his legs showed edema of the proximal
muscles, particularly of both adductors. A biopsy of
adductor muscle tissue was performed. Histological and
immunohistochemical tests (inflammation marker,
membrane attack complex, and major histocompatibility
complex class I) showed signs of muscle necrosis (Figure
1, Figure 2) and diffuse muscle infiltration of T lympho-
cytes (Figure 3), but no signs of an autoimmune process.
Additional serological tests for hepatitis B, hepatitis C,
anti-nuclear antibodies, anti-neutrophil cytoplasmic anti-
bodies, anti-double-stranded DNA antibodies, anti-mito-
chondrial M2 antibodies (anti-Mi2), anti-signal
recognition particle (anti-SRP) antibodies, anti-Jo-1 anti-
bodies and anti-polymyositis/scleroderma antibodies
(anti-PM-Scl) all yielded negative results.
The patient was rehydrated with bicarbonate solution
until his jugular veins were distended, and therapy with
intravenous furosemide, ceftriaxone, methylprednisolone
(500 mg/day), calcium, vitamin D, and alendronate was
initiated. The patient’s proximal muscle weakness
declined within three days. Within four days, his serum
creatinine level rose to 190 μmol/L, which was
accompanied by oliguria, and his serum creatine kinase
level dropped from a maximum of 169,910 U/L to
34,897 U/L. His steroid therapy was modified to oral
prednisone 80 mg/day. Seven days later he could walk
again with support, and his urine output and serum
creatinine level had normalized. After 28 days, his pre-
dnisone treatment was tapered back to 35 mg/day, but
within four days his serum creatine kinase rose again
from 547 U/L to 1548 U/L without clinical
Figure 1 Cross-sectional slice of human skeletal muscle
showing acute muscle fiber necrosis (hematoxylin and eosin
stain; × 400 original magnification).
Figure 2 Cross-sectional slice of human skeletal muscle
(hematoxylin and eosin stain; × 400 original magnification).
Regenerating muscle fibers can be seen as basophilic fibers with
enlarged nuclei in the center of the image.
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deterioration. His prednisone dosage was increased to
70 mg/day, and his serum creatine kinase declined to
normal (246 U/L) within six weeks. The patient was dis-
charged from the hospital free of symptoms after under-
going orchiectomy on the 45th day following his initial
admission. His serum creatine kinase and serum creati-
nine were normal, and he was prescribed prednisone 50
mg/day. After his discharge from the hospital, predni-
sone was tapered to 20 mg/day and his serum creatine
kinase level rose slightly without clinical relapse. Nine
months after discharge his prednisone therapy was
stopped without a subsequent increase in his creatine
kinase level. At his 12-month follow-up examination,
the patient was in good clinical condition and had nor-
mal laboratory values, including PSA.
Discussion
Myopathy with rhabdomyolysis and renal failure can have
several causes. In the course of searching for a possible
inflammatory myopathy, we found no clinical or serologi-
cal signs of endocrinopathies, viral infections, or connec-
tive tissue diseases and no immunohistochemical signs of
autoimmune polymyositis or dermatomyositis. The nega-
tive results of screening of our patient for these antibodies
represent an additional argument against a diagnosis of
autoimmune polymyositis, although anti-Jo-1 antibodies
are found in 18% to 55% of these patients, anti-Mi-2 anti-
bodies are found in 4% to 9%, anti-SRP antibodies are
found in 4.8% to 11% of patients with autoimmune poly-
myositis, and anti-PM-Scl antibodies are found in 25% of
patients with concomitant polymyositis and scleroderma
[8-10]. Although cancer-associated myopathy can be of
inflammatory origin [11], we assume that a paraneoplastic
etiology of the myositis in our patient is not probable.
While cancer-associated myositis can ameliorate during
cancer treatment [7], the treatment of cancer in our
patient resulted in the development of clinical signs of
myopathy. On the basis of his serum PSA and the fact that
the size of the solitary node in his lung decreased during
leuprolide acetate therapy, we assume that prostate cancer
therapy was successful in our patient.
We consider leuprolide acetate to be the cause of
myopathy in our patient. We did not find an infectious
cause of his myopathy. However, T lymphocytes were
found. Thus, it is likely that a drug-induced T-lympho-
cyte-mediated mechanism, not a direct toxic effect of
leuprolide acetate, caused his muscle necrosis. We can-
not explain the exact mechanism. Further studies are
required to answer this question.
To the best of our knowledge, this is the fourth such
case reported in the literature. The three previously
published cases manifested with proximal myopathy.
While the muscle biopsy in the first case showed diffuse
T-lymphocyte infiltration of the muscle and was treated
with steroids [12], the biopsy in the second case
revealed only mild, non-specific changes [13]. In the
third case, no biopsy was performed [14]. In these three
studies, the reported serum creatine kinase values were
2728 U/L, normal, and 1290 U/L, respectively, and
within one to six months after leuprolide acetate therapy
was discontinued, the patients’ symptoms of myopathy
vanished. Renal failure did not occur.
Conclusion
In this case report, we highlight rare but severe side
effects of leuprolide acetate therapy: inflammatory myo-
pathy, severe rhabdomyolysis, and renal failure. To the
best of our knowledge, this report describes the second
case of leuprolide acetate-induced inflammatory myopa-
thy and the first case of severe leuprolide acetate-
induced rhabdomyolysis with renal failure.
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